Catalogue Number
BD-P0124
Analysis Method
Specification
95.0%(HPLC)
Storage
-20℃
Molecular Weight
1063.23
Appearance
White powder
Botanical Source
This product is isolated and purified from the roots of Dioscorea opposita Thunb.
Structure Type
Category
SMILES
CC1C2C(CC3C2(CCC4C3CC=C5C4(CCC(C5)OC6C(C(C(C(O6)CO)OC7C(C(C(C(O7)C)O)O)O)O)OC8C(C(C(C(O8)C)O)O)O)C)C)OC1(CCC(C)COC9C(C(C(C(O9)CO)O)O)O)OC
Synonyms
β-D-Glucopyranoside, (3β,22β,25R)-26-(β-D-glucopyranosyloxy)-22-methoxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1->2)-O-[6-deoxy-α-L-mannopyranosyl-(1->4)]-/(3β,22R,25R)-26-(β-D-Glucopyranosyloxy)-22-methoxyfurost-5-en-3-yl 6-deoxy-α-L-mannopyranosyl-(1->2)-[6-deoxy-α-L-mannopyranosyl-(1->4)]-β-D-glucopyranoside/methyl protoneodioscin/Methyl Protodioscin
IUPAC Name
Applications
In vivo antiosteoporotic activity of a fraction of Dioscorea spongiosa and its constituent, 22-O-methylprotodioscin.[Pubmed: 15114498]Planta Med. 2004 Mar;70(3):220-6. Methyl protodioscin (NSC-698790) was a furostanol saponin isolated from the rhizome of Dioscorea collettii var. hypoglauca (Dioscoreaceae), a Chinese herbal remedy for the treatment of cervical carcinoma, carcinoma of the urinary bladder, and renal tumors for centuries. METHODS AND RESULTS: To systematically evaluate its potential anticancer activity, Methyl protodioscin was tested cytotoxicity in vitro against human cancer cell lines by the NCI's (National Cancer Institute) anticancer drug screen. As a result, Methyl protodioscin showed strong cytotoxicity against most cell lines from solid tumors with GI50 < or = 10.0 microM, especially selectively against one colon cancer line (HCT-15) and one breast cancer line (MDA-MB-435) with GI50 < 2.0 microM but moderate cytotoxicity was shown against leukemia cell lines with GI50 10-30 microM. The data are consistent with the fact that the rhizome of D. collettii var. hypoglauca has been employed for the treatment of solid tumors rather than leukemia in China for centuries. CONCLUSIONS: Based on an analysis using the COMPARE computer program with Methyl protodioscin as a seed compound, no compounds in the NCI's anticancer drug screen database have cytotoxicity patterns similar to those of Methyl protodioscin, indicating a potential novel mechanism of anticancer action.
Density
1.4±0.1 g/cm3
Solubility
Methanol
Flash Point
Boiling Point
Melting Point
InChl
InChl Key
HSSJYSJXBOCKQM-LXNCCRCLSA-N
WGK Germany
RID/ADR
HS Code Reference
Personal Projective Equipment
Correct Usage
For Reference Standard and R&D, Not for Human Use Directly.
Meta Tag
provides coniferyl ferulate(CAS#:54522-52-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
No Technical Documents Available For This Product.
24824535
Background
The absence of evidence-based guidelines for prostate cancer treatment led the Institute of Medicine to include localized prostate cancer treatment among the 25 most important topics for comparative effectiveness research.
Objective
This study compared prostate cancer treatment and survival in men with and without prevalent comorbid conditions.
Research Design
The sample comprised elderly men, aged 66 years and older, extracted from SEER-Medicare data, 2004-2009 (N=73,563). Treatment and survival for men with at least one of four prevalent comorbid conditions were compared to men who did not have any of the 12 Charlson comorbid conditions. The sample was stratified by comorbid condition and low, intermediate, and high risk disease.
Results
Over half of men received some form of cancer-directed treatment, regardless of comorbid condition. Men who have Congestive Heart Failure (CHF) or multiple comorbid conditions were less likely to be treated, whereas men with diabetes were more likely to be treated. With the exception of men with CHF, men with comorbid conditions and low risk disease received no survival benefit from any type of treatment.
Conclusions
Most men received treatment, particularly radiation therapy, regardless of comorbid condition. The evidence suggests more caution should be used when treating men with low risk disease and comorbid conditions as they are at risk for adverse events and additional medical costs, without a survival benefit.
Prostate Cancer Treatment and Survival: Evidence for Men with Prevalent Comorbid Conditions
Cathy J. Bradley, Ph.D.,corresponding author Bassam Dahman, Ph.D., and Mitchell Anscher, M.D.
2015 Jun 1
27365535
The effect of air pollution on the changing pattern of glomerulopathy has not been studied. We estimated the profile of and temporal change in glomerular diseases in an 11-year renal biopsy series including 71,151 native biopsies at 938 hospitals spanning 282 cities in China from 2004 to 2014, and examined the association of long-term exposure to fine particulate matter of <2.5 μm (PM2.5) with glomerulopathy. After age and region standardization, we identified IgA nephropathy as the leading type of glomerulopathy, with a frequency of 28.1%, followed by membranous nephropathy (MN), with a frequency of 23.4%. Notably, the adjusted odds for MN increased 13% annually over the 11-year study period, whereas the proportions of other major glomerulopathies remained stable. During the study period, 3-year average PM2.5 exposure varied among the 282 cities, ranging from 6 to 114 μg/m3 (mean, 52.6 μg/m3). Each 10 μg/m3 increase in PM2.5 concentration associated with 14% higher odds for MN (odds ratio, 1.14; 95% confidence interval, 1.10 to 1.18) in regions with PM2.5 concentration >70 μg/m3. We also found that higher 3-year average air quality index was associated with increased risk of MN. In conclusion, in this large renal biopsy series, the frequency of MN increased over the study period, and long-term exposure to high levels of PM2.5 was associated with an increased risk of MN.
renal biopsy, membranous nephropathy, air pollution
Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China
Xin Xu,* Guobao Wang,* Nan Chen,† Tao Lu,* Sheng Nie,* Gang Xu,‡ Ping Zhang,§ Yang Luo,‖ Yongping Wang,* Xiaobin Wang,¶ Joel Schwartz,** Jian Geng,corresponding author††‡‡ and Fan Fan Houcorresponding author*
2016 Jun 30
23331464
Objectives
• To quantify the impact of androgen deprivation therapy (ADT) in men with a high baseline risk of skeletal complications and evaluate the risk of mortality after a fracture.
Patients and methods
• We studied 75 994 men, aged ≥ 66 years, with localized prostate cancer from the Surveillance, Epidemiology and End Results-Medicare linked data.
• Cox proportional hazard models were employed to evaluate the risk.
Results
• Men with a high baseline risk of skeletal complications have a higher probability of receiving ADT than those with a low risk (52.1% vs 38.2%, P < 0.001).
• During the 12-year follow-up, more than 58% of men with a high risk and 38% of men with a low risk developed at least one fracture after ADT.
• The dose effect of ADT is stronger among men who received ADT only compared to those who received ADT with other treatments.
• In the high-risk group, the fracture rate increased by 19.9 per 1000 person-years (from 52.9 to 73.0 person-years) for men who did not receive ADT compared to those who received 18 or more doses of gonadotropin-releasing hormone agonist among men who received ADT only, and by 14.2 per 1000 person-years (from 45.2 to 59.4 person-years) among men who received ADT and other treatments.
• Men experiencing a fracture had a 1.38-fold higher overall mortality risk than those who did not (95% CI, 1.34-1.43).
Conclusions
• Men with a high baseline risk of skeletal complications developed more fractures after ADT.
• The mortality risk is 40% higher after experiencing a fracture.
• Consideration of patient risk before prescribing ADT for long-term use may reduce both fracture risk and fracture-associated mortality.
ADT, baseline risk, fracture, prostate cancer
Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications
Yu-Hsuan Shao,*† Dirk F. Moore,*‡ Weichung Shih,*‡ Yong Lin,*‡ Thomas L. Jang,* and Grace L. Lu-Yao*†
2014 May 1